Skip to main content
    M

    Merck & Company Inc (MRK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $144.52
    -3.24 (-2.19%)

    Market Cap: $364.26B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Merck & Company Inc (MRK) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Merck & Company reported revenue of $65.01B for the fiscal year ended Dec 31, 2025, up 1.3% from the year before. That year, net income was $18.26B with a net margin of 28.1%, operating cash flow was $16.47B and free cash flow was $12.36B. The quarter ended Sep 30, 2026 had revenue of $18.09B and net income of $5.07B.

    Revenue and Margins

    The operating margin was 32.6% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $39.81B, a compound annual rate of 5.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$65.01B+1.3%74.8%32.6%28.1%
    Dec 2024$64.17B+6.7%76.3%31.0%26.7%
    Dec 2023$60.12B+1.4%73.2%3.9%0.6%
    Dec 2022$59.28B+21.7%70.6%30.3%24.5%
    Dec 2021$48.70B+17.3%72.0%25.7%26.8%
    Dec 2020$41.52B+6.1%67.2%12.0%17.0%
    Dec 2019$39.12B-7.5%69.3%18.7%24.9%
    Dec 2018$42.29B+5.4%68.1%19.6%14.6%
    Dec 2017$40.12B+0.8%67.8%15.0%6.0%
    Dec 2016$39.81BN/A64.8%12.2%9.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 6.6% from the year before. In the quarter ended Sep 2026, net income fell 12.4% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$65.01B$64.17B$60.12B$59.28B$48.70B$41.52B$39.12B$42.29B$40.12B$39.81B
    Cost of revenue$16.38B$15.19B$16.13B$17.41B$13.63B$13.62B$12.02B$13.51B$12.91B$14.03B
    Gross profit$48.63B$48.98B$43.99B$41.87B$35.08B$27.90B$27.11B$28.79B$27.21B$25.78B
    Research and development$15.79B$17.94B$30.53B$13.55B$12.24B$13.40B$9.72B$9.75B$10.34B$10.26B
    Operating income$21.22B$19.91B$2.35B$17.95B$12.54B$4.97B$7.30B$8.30B$6.02B$4.85B
    Net income$18.26B$17.13B$377.00M$14.53B$13.05B$7.07B$9.76B$6.19B$2.42B$3.94B
    EBITDA$26.91B$24.43B$5.76B$20.35B$17.09B$9.35B$10.48B$13.22B$11.20B$10.13B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$18.09B$16.61B$16.29B$16.40B$17.28B$15.81B$15.53B$15.62B$16.66B$16.11B$15.78B$14.63B
    Gross profit$13.19B$12.21B$12.09B$10.85B$13.42B$12.25B$12.11B$11.80B$12.58B$12.37B$12.23B$10.72B
    Operating income$5.59B-$584.00M-$3.40B$3.85B$6.51B$4.99B$5.87B$4.30B$3.93B$6.05B$5.64B-$1.97B
    Net income$5.07B-$1.34B-$4.24B$2.96B$5.79B$4.43B$5.08B$3.74B$3.16B$5.46B$4.77B-$1.23B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $49.34B exceeded cash and equivalents by $34.77B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$136.87B$117.11B$106.67B$109.16B$105.69B$91.59B$84.40B$82.64B$87.87B$95.38B
    Current assets$43.52B$38.78B$32.17B$35.72B$30.27B$27.76B$27.48B$25.88B$24.77B$30.61B
    Cash and equivalents$14.56B$13.24B$6.84B$12.69B$8.10B$8.05B$9.68B$7.96B$6.09B$6.51B
    Total liabilities$84.20B$70.73B$69.04B$63.10B$67.44B$66.18B$58.40B$55.76B$53.30B$55.07B
    Short-term debt$2.59B$2.65B$1.37B$1.95B$2.41B$6.43B$3.61B$5.31B$3.06B$568.00M
    Long-term debt$46.75B$34.46B$33.68B$28.75B$30.69B$25.36B$22.74B$19.81B$21.35B$24.27B
    Shareholder equity$52.61B$46.31B$37.58B$45.99B$38.18B$25.32B$25.91B$26.70B$34.34B$40.09B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$132.77B$129.80B$128.69B$136.87B$129.55B$117.52B$115.12B$117.11B$117.53B$112.63B$105.85B$106.67B
    Total liabilities$87.83B$87.82B$82.75B$84.20B$77.64B$68.46B$66.72B$70.73B$72.97B$68.98B$65.42B$69.04B
    Cash and equivalents$9.55B$6.85B$5.33B$14.56B$18.17B$8.01B$8.63B$13.24B$14.59B$11.30B$5.58B$6.84B
    Shareholder equity$44.89B$41.93B$45.88B$52.61B$51.85B$48.99B$48.34B$46.31B$44.50B$43.58B$40.36B$37.58B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 75.0% of operating cash flow. Dividends and share repurchases together came to 107.3% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$16.47B$21.47B$13.01B$19.09B$13.12B$7.62B$8.88B$10.92B$6.45B$10.38B
    Capital expenditures$4.11B$3.37B$3.86B$4.39B$4.45B$4.43B$3.37B$2.62B$1.89B$1.61B
    Free cash flow$12.36B$18.10B$9.14B$14.71B$8.67B$3.19B$5.51B$8.31B$4.56B$8.76B
    Dividends paid$8.18B$7.84B$7.45B$7.01B$6.61B$6.21B$5.70B$5.17B$5.17B$5.12B
    Share repurchases$5.08B$1.31B$1.35B$0$840.00M$1.28B$4.78B$9.09B$4.01B$3.43B
    Investing cash flow-$13.74B-$7.73B-$14.08B-$4.96B-$16.42B-$9.19B-$2.53B$4.31B$2.68B-$3.21B
    Financing cash flow-$1.92B-$7.03B-$4.81B-$9.12B$3.10B-$2.83B-$8.86B-$13.16B-$10.01B-$9.04B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$6.56B$5.37B$3.92B$2.86B$7.82B$3.29B$2.50B$3.45B$9.29B$5.64B$3.09B$246.00M
    Capital expenditures$1.04B$893.00M$991.00M$1.03B$987.00M$764.00M$1.33B$937.00M$783.00M$791.00M$861.00M$989.00M
    Free cash flow$5.52B$4.48B$2.93B$1.82B$6.83B$2.53B$1.17B$2.51B$8.51B$4.85B$2.23B-$743.00M
    Last 12 quarters

    Frequently Asked Questions About MRK

    What is Merck & Company's annual revenue?

    Merck & Company reported revenue of $65.01B for the fiscal year ended Dec 31, 2025.

    How fast is Merck & Company's revenue growing?

    Revenue was up 1.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.1%.

    Is Merck & Company profitable?

    Yes. Merck & Company reported net income of $18.26B for the fiscal year ended Dec 31, 2025, with a net margin of 28.1%.

    How much free cash flow does MRK generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $16.47B minus capital expenditures of $4.11B produced free cash flow of $12.36B.

    How much debt does Merck & Company have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $46.75B, short-term debt of $2.59B and cash and equivalents of $14.56B.